Small-scale technologies, such as nanotechnology and microfluidics, may provide new tools for medicine. These emerging technologies have the potential to change the face of medicine. For example, gold nanoparticles may provide clinical diagnostic assays that are more accurate and predictive than existing ones. We found that gold nanoparticles may be very effective against multi-drug resistant bacteria, even though gold by itself is not an effective antibiotic.  Another example is that microfluidic chips can rapidly screen drugs, in particular, nano-formulations, against drugs that can be used to combat cancer. In terms of clinical translation, some of these tools have started to be useful in the clinics, in particular, medical devices whose core technologies are based on these tools have found initial commercial applications in the clinics.

Xingyu Jiang is a Professor at the National Center for NanoScience and Technology (NCNST) and the University of the Chinese Academy of Sciences. He obtained his BS at the University of Chicago (1999) and PhD at Harvard University (with Prof. George Whitesides, 2004). He started in the NCNST in 2005 and has remained there since. His research interests include microfluidics and nanoparticles and their biomedical applications. He was awarded the “Hundred Talents Plan” of the Chinese Academy of Sciences, the National Science Foundation of China’s Distinguished Young Scholars Award, the Scopus Young Researcher Gold Award, the Human Frontier Science Program Young Instigator Award. He is a Fellow of the Royal Society of Chemistry, an associate editor of Nanoscale (Royal Society of Chemistry, UK). He has published over 200 peer-reviewed papers and is the inventor of over 100 patents.

 

About CCR Seminars

The UQ Centre of Clinical Research Seminars (CCR) are held fortnightly on Wednesdays from 12pm - 1pm (except during school holidays) in the CCR Auditorium, Herston. The series features topics in the following fields of research, presented by invited international, interstate and local researchers.